^
    Back
    Association details:
    Biomarker:MYC overexpression
    Cancer:Triple Negative Breast Cancer
    Drug Class:PD-L1 inhibitor +
    MYC inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Immunol Res
    Title:

    Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer

    Published date:
    07/01/2022
    Excerpt:
    Finally, a small-molecule inhibitor of MYC combined with PD-L1 blockade elicited a durable response in immune-cold TNBC with high MYC expression, suggesting a strategy to restore PD-L1 inhibitor sensitivity in MYC-overexpressing TNBC.
    DOI:
    10.1158/2326-6066.CIR-21-0826